235 related articles for article (PubMed ID: 24771494)
21. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Steinherz PG; Shukla N; Kobos R; Steinherz L
Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
[TBL] [Abstract][Full Text] [Related]
22. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
[TBL] [Abstract][Full Text] [Related]
23. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
[TBL] [Abstract][Full Text] [Related]
24. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
[TBL] [Abstract][Full Text] [Related]
25. A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Horton TM; Perentesis JP; Gamis AS; Alonzo TA; Gerbing RB; Ballard J; Adlard K; Howard DS; Smith FO; Jenkins G; Kelder A; Schuurhuis GJ; Moscow JA
Pediatr Blood Cancer; 2014 Oct; 61(10):1754-60. PubMed ID: 24976003
[TBL] [Abstract][Full Text] [Related]
26. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
27. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
[TBL] [Abstract][Full Text] [Related]
28. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
Takahashi K; Kantarjian H; Garcia-Manero G; Borthakur G; Kadia T; DiNardo C; Jabbour E; Pierce S; Estrov Z; Konopleva M; Andreeff M; Ravandi F; Cortes J
Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):163-8.e1-2. PubMed ID: 26752456
[TBL] [Abstract][Full Text] [Related]
29. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.
Messinger Y; Boklan J; Goldberg J; DuBois SG; Oesterheld J; Abla O; Martin A; Weinstein J; Hijiya N
Pediatr Hematol Oncol; 2017 May; 34(4):187-198. PubMed ID: 29039989
[TBL] [Abstract][Full Text] [Related]
30. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Foster MC; Amin C; Voorhees PM; van Deventer HW; Richards KL; Ivanova A; Whitman J; Chiu WM; Barr ND; Shea T
Leuk Lymphoma; 2012 Jul; 53(7):1331-7. PubMed ID: 22149206
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Hijiya N; Thomson B; Isakoff MS; Silverman LB; Steinherz PG; Borowitz MJ; Kadota R; Cooper T; Shen V; Dahl G; Thottassery JV; Jeha S; Maloney K; Paul JA; Barry E; Carroll WL; Gaynon PS
Blood; 2011 Dec; 118(23):6043-9. PubMed ID: 21967976
[TBL] [Abstract][Full Text] [Related]
32. Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.
Thomas X; de Botton S; Chevret S; Caillot D; Raffoux E; Lemasle E; Marolleau JP; Berthon C; Pigneux A; Vey N; Reman O; Simon M; Recher C; Cahn JY; Hermine O; Castaigne S; Celli-Lebras K; Ifrah N; Preudhomme C; Terré C; Dombret H
J Clin Oncol; 2017 Apr; 35(11):1223-1230. PubMed ID: 28221862
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Jeha S; Razzouk B; Rytting M; Rheingold S; Albano E; Kadota R; Luchtman-Jones L; Bomgaars L; Gaynon P; Goldman S; Ritchey K; Arceci R; Altman A; Stine K; Steinherz L; Steinherz P
J Clin Oncol; 2009 Sep; 27(26):4392-7. PubMed ID: 19652076
[TBL] [Abstract][Full Text] [Related]
34. A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Burnett AK; Russell NH; Hills RK; Kell J; Nielsen OJ; Dennis M; Cahalin P; Pocock C; Ali S; Burns S; Freeman S; Milligan D; Clark RE
Leukemia; 2017 Feb; 31(2):310-317. PubMed ID: 27624670
[TBL] [Abstract][Full Text] [Related]
35. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Advani AS; McDonough S; Coutre S; Wood B; Radich J; Mims M; O'Donnell M; Elkins S; Becker M; Othus M; Appelbaum FR
Br J Haematol; 2014 May; 165(4):504-9. PubMed ID: 24579885
[TBL] [Abstract][Full Text] [Related]
36. Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults.
Tran H; Yang D
Ann Pharmacother; 2012 Jan; 46(1):89-96. PubMed ID: 22170975
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.
Jacoby MA; Martin MG; Uy GL; Westervelt P; Dipersio JF; Cashen A; Stockerl-Goldstein K; Vij R; Luo J; Reineck T; Bernabe N; Abboud CN
Am J Hematol; 2014 May; 89(5):487-92. PubMed ID: 24415560
[TBL] [Abstract][Full Text] [Related]
39. Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Knoebel RW; McQuary A; Becker P; Hendrie P; Petersdorf S; Appelbaum FR; Estey E
Leuk Res; 2011 Sep; 35(9):e164-6. PubMed ID: 21684006
[No Abstract] [Full Text] [Related]
40. Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan.
Suzuki T; Yamauchi T; Ando K; Nagai T; Kakihana K; Miyata Y; Uchida T; Tabata Y; Ogura M
Jpn J Clin Oncol; 2013 Dec; 43(12):1177-83. PubMed ID: 24130086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]